Iovance Biotherapeutics Inc. (0JDK) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Iovance Biotherapeutics Inc. $1.85, price $14.23, upside -87.0%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Iovance Biotherapeutics Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $1.68 – $52.55 · fair‑value band $1.22 – $2.31 · the $14.23 price screens above the $1.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Iovance Biotherapeutics in your weekly email
Every Wednesday you see whether Iovance Biotherapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Show more
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Stock analysis
Iovance Biotherapeutics Inc. (0JDK) currently trades at $14.23, while our model-based Fair Value estimate is $1.85, 87.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the evidence level at low.
Scenario range: $1.22 (bear) to $2.31 (bull), the price of $14.23 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Industrials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Iovance Biotherapeutics Inc. reported revenue of $264M in FY2025 versus $1.2M in FY2023, a compound +1,388.7%/yr. Reported net income was −$391M in FY2025.
Key figures
Market cap $5.1B · EPS (TTM) $−2.30 · Net margin −148% · Return on equity −47.5% · Return on assets (EBIT) −50.0% · Operating margin −113% · Revenue (TTM) $286M · Revenue growth (YoY) +44.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 694% above its 52-week low.
For context, the median of 10 Industrials peers we cover trades at 10% fair-value upside, at −87%, 0JDK screens richer than that median.
Fair Value models
Bear $1.22Fair Value $1.85Bull $2.31
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Iovance Biotherapeutics Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 624 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score36 · Below median
Fair Value upside−87.0% · Bottom 25%
Profitability
Return on assets−23.7% · Below median
Net margin (TTM)−123.9% · Bottom 25%
Operating margin (TTM)−113.5% · Bottom 25%
Growth and dividend
Revenue growth44.8% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B7.27× · Priciest 25%
P/S (TTM)17.78× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Iovance Biotherapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/0JDK
Frequently asked questions
Is Iovance Biotherapeutics Inc. (0JDK) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $1.85 versus a price of $14.23, about −87% upside (overvalued).
What is the fair value of 0JDK?
Our model-based fair value for Iovance Biotherapeutics Inc. is $1.85 (as of Sep 24, 2026), built from audited fundamentals. The current price: $14.23.
What is the quality score of 0JDK?
Iovance Biotherapeutics Inc. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Iovance Biotherapeutics Inc. (0JDK)?
Our model-based price target is the fair value of $1.85 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $1.22, optimistic scenario $2.31. It is a calculation from audited fundamentals, not an analyst target.
What is the Iovance Biotherapeutics Inc. stock forecast for 2026?
Our models put fair value at $1.85, about −87% upside versus a price of $14.23 (overvalued). Cautious scenario $1.22, optimistic scenario $2.31. The calculation is refreshed regularly with new filings.
What is the revenue of Iovance Biotherapeutics Inc. (0JDK)?
Iovance Biotherapeutics Inc. reported trailing-twelve-month revenue of about $286M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Iovance Biotherapeutics Inc. (0JDK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Iovance Biotherapeutics Inc. it is $1.85 per share (as of Sep 24, 2026), against a price of $14.23. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Iovance Biotherapeutics Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0JDK trades above its calculated fair value: price $14.23, fair value $1.85, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0JDK?
No. The price is what the market pays today ($14.23); the fair value is what the company's own numbers justify ($1.85). For Iovance Biotherapeutics Inc. the two are $12.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is Iovance Biotherapeutics Inc. worth?
The market values Iovance Biotherapeutics Inc. at about $5.1B (market capitalisation, as of Sep 24, 2026). Per share that is $14.23; our models calculate a fair value of $1.85 per share.
What do the bullish and bearish scenarios say about 0JDK?
Our models span a range for Iovance Biotherapeutics Inc.: cautious scenario $1.22, base $1.85, optimistic $2.31 per share (as of Sep 24, 2026, price $14.23). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Iovance Biotherapeutics Inc. (0JDK)?
Balance-sheet figures for Iovance Biotherapeutics Inc. (as of Sep 24, 2026): return on equity −47.5%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 0JDK from its 52-week high?
Iovance Biotherapeutics Inc. trades at $14.23, about 5% below its 52-week high of $14.99 and 694% above the low of $1.79 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.85 is for.
Which stocks are comparable to Iovance Biotherapeutics Inc.?
From the same area (Industrials) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Iovance Biotherapeutics Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price $14.23, calculated fair value $1.85 (−87%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0JDK calculated?
We run Iovance Biotherapeutics Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Iovance Biotherapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Iovance Biotherapeutics Inc. (0JDK)?
The closing price on Oct 2, 2026 was $14.23. Our model-based fair value is $1.85, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Iovance Biotherapeutics Inc. right now?
The price sits above even our optimistic bull case ($2.31). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.22 to $2.31) leaves room in how you read the outcome.
Key figures of Iovance Biotherapeutics Inc.
How large is the market capitalisation of Iovance Biotherapeutics Inc. (0JDK)?
The market capitalisation of Iovance Biotherapeutics Inc. is $5.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Iovance Biotherapeutics Inc. (0JDK)?
Earnings per share at Iovance Biotherapeutics Inc. are $−2.30. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Iovance Biotherapeutics Inc. (0JDK)?
The net margin of Iovance Biotherapeutics Inc. is −148% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Iovance Biotherapeutics Inc. (0JDK)?
The return on equity (ROE) of Iovance Biotherapeutics Inc. is −47.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Iovance Biotherapeutics Inc. (0JDK)?
On an EBIT basis the return on assets of Iovance Biotherapeutics Inc. is −50.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Iovance Biotherapeutics Inc. (0JDK)?
The operating margin of Iovance Biotherapeutics Inc. is −113% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Iovance Biotherapeutics Inc. (0JDK)?
Revenue at Iovance Biotherapeutics Inc. is growing +44.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Iovance Biotherapeutics Inc. (0JDK) generate?
The free cash flow of Iovance Biotherapeutics Inc. is −$336M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Iovance Biotherapeutics Inc. (0JDK) hold?
Iovance Biotherapeutics Inc. holds more cash than debt, $69.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Iovance Biotherapeutics Inc. in the live analysis
One click puts Iovance Biotherapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
